ArticleACS nano2014
Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release.
Article in ACS nano, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 219 citations in OpenAlex.
- Clinical validation of a nanodiamond-embedded thermoplastic biomaterial.Proceedings of the National Academy of Sciences of the United States of America · 2017Trial
- Nanomaterial-enabled smart contact lenses: bridging sensing, therapy, and theranostics for next-generation ocular healthcare.Journal of nanobiotechnology · 2026Review
- Next-generation smart ophthalmic biomaterials: From passive response to active interaction and closed-loop control.Bioactive materials · 2026Review
- Simultaneous sustained delivery of NSAID bromfenac and lubricant polyvinylpyrrolidone by vitamin E nanobarrier contact lenses.Journal of drug delivery science and technology · 2026Article
- Nanotechnology-Based Treatment for Ophthalmic Diseases.International journal of nanomedicine · 2026Review
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Nanogels as Drug Delivery Carrier: A Narrative Review on Formulation Techniques, Characterization, Applications and Patents.Current pharmaceutical biotechnology · 2025Review
- From Vision Correction to Drug Delivery: Unraveling the Potential of Therapeutic Contact Lens.Current drug delivery · 2025Review
- Chitosan nanoparticles laden contact lenses for enzyme-triggered controlled delivery of timolol maleate: A promising strategy for managing glaucoma.Drug delivery and translational research · 2024Article
- Co-delivery of Brinzolamide and Timolol from Micelles-laden Contact Lenses: In vitro and In Vivo Evaluation.Pharmaceutical research · 2024Article
- Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders.Current drug research reviews · 2024Review
- Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases.Drug delivery · 2023Review
- Recent advancements in nanomaterial-laden contact lenses for diagnosis and treatment of glaucoma, review and update.Journal of nanobiotechnology · 2023Review
- Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies.Journal of clinical medicine · 2023Review
- Contact lens as an emerging platform for ophthalmic drug delivery: A systematic review.Asian journal of pharmaceutical sciences · 2023Review
- Advances in Nanogels for Topical Drug Delivery in Ocular Diseases.Gels (Basel, Switzerland) · 2023Review
- Biopolymeric Coatings for Local Release of Therapeutics from Biomedical Implants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin.Journal of advanced research · 2023Article
- Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.Annals of medicine · 2022Article
- Wireless theranostic smart contact lens for monitoring and control of intraocular pressure in glaucoma.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Temporarily implanted devices, such as drug-loaded contact lenses, are emerging as the preferred treatment method for ocular diseases like glaucoma. Localizing the delivery of glaucoma drugs, such as timolol maleate (TM), can minimize adverse effects caused by systemic administration. Although eye drops and drug-soaked lenses allow for local treatment, their utility is limited by burst release and a lack of sustained therapeutic delivery. Additionally, wet transportation and storage of drug-soaked lenses result in drug loss due to elution from the lenses. Here we present a nanodiamond (ND)-embedded contact lens capable of lysozyme-triggered release of TM for sustained therapy. We find that ND-embedded lenses composed of enzyme-cleavable polymers allow for controlled and sustained release of TM in the presence of lysozyme. Retention of drug activity is verified in primary human trabecular meshwork cells. These results demonstrate the translational potential of an ND-embedded lens capable of drug sequestration and enzyme activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.